Author

Ayelet Cahana

Observed institution: Novartis (United States)

OpenAlex ID: A5049999075

Everolimus Plus Exemestane in Postmenopausal Patients with HR+ Breast Cancer: BOLERO-2 Final Progression-Free Survival Analysis

2013 · Denise A. Yardley, Shinzaburo Noguchi, et al. · Advances in Therapy · 525

Everolimus for postmenopausal women with advanced breast cancer: Updated results of the BOLERO-2 phase III trial.

2012 · Martine J. Piccart-Gebhart, Shinzaburo Noguchi, et al. · Journal of Clinical Oncology · 42

Health-related quality of life and disease symptoms in postmenopausal women with HR+, HER2−advanced breast cancer treated with everolimus plus exemestane versus exemestane monotherapy

2013 · Mario Campone, J. Thaddeus Beck, et al. · Current Medical Research and Opinion · 24

Everolimus for postmenopausal women with advanced breast cancer: Updated results of the BOLERO-2 phase III trial.

2012 · Francis P. Arena, Shinzaburo Noguchi, et al. · Journal of Clinical Oncology · 16

Erratum to: Everolimus Plus Exemestane in Postmenopausal Patients with HR+ Breast Cancer: BOLERO-2 Final Progression-Free Survival Analysis

2014 · Denise A. Yardley, Shinzaburo Noguchi, et al. · Advances in Therapy · 1

Works count: 5

Citation count: 608

H-index: 4

I10-index: 4